CN111110663A

CN111110663A - Application of phloroglucinol aldehyde and composition containing phloroglucinol aldehyde

Info

Publication number: CN111110663A
Application number: CN201911277206.8A
Authority: CN
Inventors: 伍树松; 谭继君; 刘明; 胡睿智; 李岩利; 何子煜; 贺建华; 张宏福
Original assignee: Beijing Zhongnong Hongke Biotechnology Co ltd; Hunan Agricultural University
Current assignee: Beijing Zhongnong Hongke Biotechnology Co ltd; Hunan Agricultural University
Priority date: 2019-12-12
Filing date: 2019-12-12
Publication date: 2020-05-08

Abstract

The invention relates to application of phloroglucinaldehyde (phloroglucinaldehyde) and a composition containing phloroglucinaldehyde, in particular to application of phloroglucinol aldehyde in preparing a product for preventing and/or improving symptoms caused by high-energy dietary intake, wherein the symptoms comprise obesity, metabolic diseases caused by excessive fat, liver function damage and intestinal flora disorder. The phloroglucinol has wide application prospect in the fields of medicines, foods and feeds, and when the phloroglucinol is applied to high-fat feeds, the disturbance of intestinal micro-ecological environment and the burden and damage of liver metabolism caused by high-fat daily ration can be effectively eliminated, so that the utilization rate of nutrient substances of animals can be improved, the immunity of the animals can be improved, and the production performance of the animals can be improved.

Description

Application of phloroglucinol aldehyde and composition containing phloroglucinol aldehyde

Technical Field

The invention relates to the field of biochemistry, in particular to application of phloroglucinol aldehyde and a composition containing phloroglucinol aldehyde.

Background

Anthocyanins are a secondary metabolite with a polyphenol structure that is widely found in plants. They act as important antioxidants and pigments, giving plants their characteristic color. Although anthocyanins vary among plants, six kinds of anthocyanins such as pelargonidin, cyanidin, delphinidin, peonidin, morning glory pigment, malvidin, etc. are considered as main natural anthocyanins. Berries, such as red raspberry (Rubus idaeus L.), Lonicera caerulea (Lonicera caerulea L.), and Mori fructus, have traditionally been used as folk medicines, and their extracts have recently been used for treating cardiovascular diseases, obesity, neurodegeneration, liver diseases, cancer, etc. Cyanidin-3-glucoside is one of the most common anthocyanins, and is naturally present in many plants such as black rice, black beans, purple potatoes and the like. Cyanidin-3-glucoside has strong antioxidant activity due to two hydroxyl groups on the B ring. Recent studies have shown that cyanidin-3-glucoside may act primarily through its metabolites. Through human pharmacokinetic studies, more than 20 metabolites have been identified in human serum.

Phloroglucinol is believed to be one of the major bioactive phenolic metabolites produced by C-ring cleavage of cyanidin-3-glucoside in the body, leading to metabolism. Currently, there are few applications for phloroglucinol. The liver is one of the most important metabolic organs of human and animals, and fat metabolism has very important significance on the deposition of animal fat and the improvement of meat quality. However, in animal production, high-energy daily ration is often used for improving the animal production performance, but the intestinal micro-ecological environment disorder and the liver metabolic burden and damage caused by the high-energy daily ration not only reduce the utilization rate of nutrient substances of animals, but also reduce the immune capacity of the animals, and the hidden production loss cannot be estimated. The plant polyphenol phloroglucinol aldehyde is a natural active ingredient, has the advantages of low toxic and side effects, no drug resistance and the like, and the phenol metabolites have the characteristics of wide sources, low cost, relative stability and capability of quickly and directly acting on organisms. However, the application of phloroglucinol aldehyde in improving obesity, liver metabolic burden or intestinal microbial environment disorder caused by high-energy dietary intake is not reported.

Disclosure of Invention

The invention aims to provide a new application of phloroglucinol aldehyde and a composition containing phloroglucinol aldehyde. In the process of researching phenolic metabolites of cyanidin-3-glucoside, the invention unexpectedly discovers that phloroglucinol aldehyde can effectively improve the problems of obesity, metabolic diseases, liver injury and intestinal microbial ecological environment disorder caused by high-energy diet.

To this end, according to a first aspect of the present invention, there is provided the use of phloroglucinol in the manufacture of a product for preventing and/or ameliorating symptoms caused by high-energy dietary intake, wherein the phloroglucinol is used as an active ingredient; the symptoms include obesity, metabolic diseases caused by excessive fat, liver function impairment, and intestinal flora disorder.

Further, the high energy diet is in particular a high fat diet.

Further, the metabolic diseases caused by the fat excess include type II diabetes, metabolic syndrome, cardiovascular diseases, chronic kidney diseases, breast cancer, colorectal cancer and the like.

Further, the impaired liver function includes increased serum transaminase levels, increased total liver cholesterol levels, increased total liver triglyceride levels, increased liver free radicals, decreased high density lipoprotein cholesterol levels, and a decreased ratio of high density lipoprotein cholesterol to low density lipoprotein cholesterol.

Further, the product comprises physiologically acceptable excipients.

Further, the adjuvant can be a fat-soluble carrier or a water-soluble carrier.

In a specific embodiment, the water-soluble carrier is water, the phloroglucinol aldehyde can be directly dissolved in the water, and the maximum solubility in the water is 6.6 mg/ml; above this concentration, it may be dissolved in ethanol in advance and then diluted into an aqueous solution, the maximum solubility being 210mg/ml in ethanol.

In another specific embodiment, the fat-soluble carrier is glycerol, soybean oil, lard, a high-fat ration, and the like, preferably a high-fat ration.

Further, the phloroglucinol aldehyde may be present in an amount of 0.025 to 0.4 wt%, such as 0.025 wt%, 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, based on the total weight of the product; preferably 0.1 wt%.

Further, the product is a medicine, food or feed.

In a second aspect of the present invention, there is provided a composition comprising (1) phloroglucinol aldehyde, and (2) a pharmaceutically, food or feed acceptable excipient, wherein the phloroglucinol aldehyde is present in the composition at a concentration that prevents and/or ameliorates symptoms caused by high-energy dietary intake; the symptoms comprise obesity, metabolic diseases caused by excessive fat, liver function impairment and intestinal flora disorder; the composition is a medicine, food or feed.

Further, the phloroglucinol aldehyde is present in an amount of 0.025 to 0.4 wt%, such as 0.025 wt%, 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, based on the total weight of the composition; preferably 0.1 wt%.

Further, the pharmaceutical, food or feed acceptable auxiliary materials are selected from the following group: water soluble carrier or fat soluble carrier.

In a specific embodiment, the water-soluble carrier is water, the phloroglucinol aldehyde can be directly dissolved in the water, and the maximum solubility in the water is 4.7 mg/ml; above this concentration, it may be dissolved in ethanol in advance and then diluted into an aqueous solution, with a maximum solubility of 192mg/ml in ethanol.

The composition can be a medicine, food or feed, and specifically, when the composition is a medicine, the composition can be prepared into the following dosage forms: tablets such as effervescent tablets, soft gels, capsules, pills, troches such as dragees, granules, injection solutions, powders such as injection powders which can be reconstituted into injection solutions, liquids such as sprays and the like; when the composition is a food product, the following food product can be prepared: chewing gum, gummy candy, toffee, caramel candy, soft candy, hard candy, beverages such as liquid beverages, semi-solid beverages, and the like.

In a third aspect of the present invention, there is provided a high-fat diet including phloroglucinol as an active ingredient, for preventing and/or improving symptoms caused by intake of the high-fat diet, including obesity, metabolic diseases caused by excessive fat, impaired liver function, and disorders of intestinal flora.

Further, the phloroglucinol is present in an amount of 0.025 to 0.4 wt%, such as 0.025 wt%, 0.05 wt%, 0.1 wt%, 0.2 wt%, 0.3 wt%, 0.4 wt%, based on the total weight of the high fat diet; preferably 0.1 wt%.

In a fourth aspect of the present invention, a preparation method of the high-fat feed is provided, which includes crushing a high-fat diet, and then uniformly mixing the crushed high-fat diet and phloroglucinol aldehyde in a step-by-step premixing manner.

Further, the progressive premixing is at least three stages.

Further, the preparation method comprises the step of forming the obtained mixture after uniformly mixing the high-fat daily ration and the phloroglucinol aldehyde.

Cyanidin-3-glucoside is a common natural anthocyanin and has antioxidant and anti-inflammatory effects. The catabolism of cyanidin-3-glucoside in gastrointestinal tract can produce phenolic metabolites with bioactivity such as protocatechuic acid, phloroglucinol aldehyde (shown as the following formula), vanillic acid, ferulic acid, etc., thereby improving the bioavailability of cyanidin-3-glucoside. Therefore, the invention establishes a high fat induced obesity mouse model, and determines the protective effect of phloroglucinol aldehyde on liver under high-energy diet intake and the effect of phloroglucinol aldehyde on improving fat metabolism by screening cyanidin-3-glucoside and main phenol metabolites thereof, carrying out a dose gradient test on effective phenol metabolites and combining a cell molecule test.

Compared with the prior art, the invention has the following advantages:

(1) the invention provides a new application of phloroglucinol aldehyde. Phloroglucinol is useful for preventing and/or improving symptoms caused by high energy dietary intake, such as obesity, metabolic diseases caused by excessive fat, impaired liver function, disturbance of intestinal flora, etc. Phloroglucinol aldehyde has wide application prospect in the fields of medicines, foods and feeds.

(2) Phloroglucinol aldehyde is used as a natural plant polyphenol secondary active metabolite and has the advantages of low toxic and side effects, no drug resistance and the like. In addition, with the rapid development of genetically engineered bacteria and chemical synthesis technology, production of phloroglucinol aldehyde by biological or chemical approaches is expected to be realized, and the method has better industrial practicability.

(3) The invention provides a composition containing phloroglucinol, which can effectively improve obesity, liver metabolic burden or intestinal microorganism environmental disorder caused by high-energy dietary intake.

(4) The invention provides a high-fat feed which contains phloroglucinol aldehyde as an active ingredient, and eliminates intestinal micro-ecological environment disorder and liver metabolic burden and damage caused by high-fat daily ration, thereby being beneficial to improving the utilization rate of nutrient substances of animals, improving the immunity of the animals and improving the production performance of the animals.

Drawings

Various other advantages and benefits will become apparent to those of ordinary skill in the art upon reading the following detailed description of the preferred embodiments. The drawings are only for purposes of illustrating the preferred embodiments and are not to be construed as limiting the invention. In the drawings:

fig. 1 is a photograph of a finished high fat ration containing phloroglucinol aldehyde prepared according to the present invention;

FIG. 2 is a flow chart of the experimental design;

FIG. 3 is a graph of the change in body weight of mice;

FIG. 4 is the daily energy intake level of mice;

FIG. 5 is a statistical chart of abdominal fat deposition in mice (abdominal fat weight, abdominal fat rate as an example);

FIG. 6 is a H & E image of abdominal fat of a mouse, with the left column being 100 times the field of view of the lens and the right column being 300 times the field of view of the lens, and the scale being 100 μm;

FIG. 7 is a statistical chart of the number of abdominal adipocytes in mice under 400 times of lens;

FIG. 8 is a graph of liver weight and liver index analysis of mice;

FIG. 9 is a H & E image and oil red staining of mouse liver, with 100 times of lens field of vision on the left, 300 times of lens field of vision in the middle and 100 times of lens field of vision on the right;

FIG. 10 is a histogram of serum transaminase levels (e.g., concentrations of aspartate transaminase and alanine transaminase in serum);

FIG. 11 is a histogram of blood lipid levels (taking as an example the ratio of total triglycerides, total cholesterol and HDL cholesterol to LDL cholesterol in serum);

FIG. 12 is a bar graph of the antioxidant index of liver tissue (taking 1% concentration of superoxide dismutase in liver homogenate and 10% concentration of malondialdehyde in liver homogenate as an example);

fig. 13 is a histogram of significant changes in intestinal flora according to the bacterial classification scale p: a door, c: class, o: mesh and f: family, g: belongs to the field of medicine.

Detailed Description

Exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. While exemplary embodiments of the present disclosure are shown in the drawings, it should be understood that the present disclosure may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.

In the examples below, 24C 57BL/6J test mice (SPF grade, male, 4-6 weeks old, license number: SCXK-Xiang 2016. 0002, http:// www.hnsja.com /) and irradiated poplar bedding were purchased from Swan Schrad laboratory animals, Inc., Hunan, individual animal breeding systems (LP-30LED-8AR/8ARS, http:// www.nihonika.co.jp /) were purchased from Japan, low fat diets (D12450B), high fat diets (D12492) were purchased from American Research diets (20JulesLan New Brunnick, NJ 08901USA, htps t:// Research. com.), phloroglucinol aldehyde was purchased from American Sigma; the reagents or instruments used are not indicated by manufacturers, and are all conventional reagent products which can be obtained commercially.

Example 1

(1) Intermittently (stopping once for 1-2s to avoid overheating) pulverizing high-fat daily ration by a pulverizer;

(2) adding phloroglucinol standard into the powdery high-fat daily ration according to the additive amount of 4g/kg (0.4%);

(3) mixing the standard substance and the high-fat daily ration by adopting a step-by-step premixing principle (at least three steps), and completely dissolving the standard substance in the high-fat daily ration (finely-divided particles of the standard substance cannot be seen in the mixed daily ration by spreading by hands);

(4) making the mixed ration into round mixed ration with suitable size, marking in bags, and storing in refrigerator at-20 deg.C.

Example 2

(2) adding phloroglucinol standard into the powdery high-fat daily ration according to the addition amount of 0.25g/kg (0.025%);

(4) making the mixed ration into round mixed ration with suitable size, marking in bags, and storing in refrigerator at-20 deg.C. The photo of the finished product of the embodiment is shown in fig. 1B, and fig. 1A shows that the high-fat ration without phloroglucinol aldehyde is obtained, so that the high-energy ration mixed with phloroglucinol aldehyde obtained in the embodiment has a better forming degree.

Example 3

(1) Intermittently (stopping once for 1-2s to avoid overheating) crushing high-fat daily ration by using a crusher;

(2) adding phloroglucinol standard into powdery high-fat daily ration according to the additive amount of 1g/kg (0.1%);

(4) making the mixed ration into round mixed ration with suitable size, marking in bags, and storing in refrigerator at-20 deg.C. The photo of the finished product of this example is shown in fig. 1C, and fig. 1A shows that the high-fat ration without phloroglucinol aldehyde is added, so that the high-energy ration mixed with phloroglucinol aldehyde obtained in this example has a better forming degree.

Examples of the experiments

24C 57BL/6J mice (glycolipid metabolism sensitive mice) weighing 15.3. + -. 0.57g at 4 weeks of age were purchased and pre-fed for one week. After the pre-feeding, mice were randomly divided into 4 groups of 6 replicates each using Experimental Animal Allometric Program (EAAP) randomization software, to ensure that there was no significant difference in weight between groups (ANOVA analysis), and the formal test was started, with the grouping and individual mouse weight as in table 1 (P between groups 0.4922>0.05, no significant difference, in g). During the test period, the free food intake and water drinking are ensured, the room temperature is kept constant (23 ℃), the single-cage breeding is well ventilated, the day is 12 hours (the system automatically turns off the lamp at 18: 00-6: 00), and the night is 12 hours (the system automatically turns on the lamp at 6: 00-18: 00). The test treatment is divided into 4 groups, wherein the blank group is fed with low-fat daily ration, the control group is fed with high-fat daily ration, and the drug intervention group is respectively fed with the high-fat daily ration added with 0.025 percent and 0.1 percent of phloroglucinol aldehyde. During the test period, the mental state of the mice is observed, the mice are weighed once every 3 days, the padding is replaced once, the drinking water is replaced once, the food intake of the mice is recorded every day, and the test period is 12 weeks. The experimental design diagram is shown in fig. 2.

TABLE 1 test grouping

Hereinafter, the results are expressed as mean ± standard deviation. Significance between groups was determined using one-way analysis of variance (ANOVA), Fisher Least Significant Difference (LSD) and Duncan multi-range test (SPSS21, IBM corp., Armonk, NY, USA). Different lower case letters (a, b, c..) represent significant differences between groups (p <0.05), with no significant difference (ns) assuming p > 0.05.

1, sample collection:

after 12 weeks, the mice were weighed for the last time before slaughtering, starved overnight, the fasting body weight of the mice was recorded the next day, each group of mice was placed in a sealed space of a cotton ball soaked with ether in sequence, and when the mice were unstable, the mice were immediately taken out for blood sampling by eyeballs (the mice were not anesthetized). Immediately collecting the blood of the mouse by using a 1.5ml centrifuge tube, standing for 30 minutes at room temperature, centrifuging (1500 Xg), collecting the upper serum, taking the serum (300-. Dissecting a mouse, observing the liver condition of the mouse (liver samples are quickly and lightly rinsed in ice normal saline, redundant blood is removed, sterile filter paper is used for sucking and weighing, the color of the liver is recorded, whether whitening exists, fat accumulation exists, whether blackening exists, fibrosis necrosis exists, 2 parts of small nail cover size samples (one part is used for H & E dyeing of the liver and the other part is used for red dyeing of liver oil) are taken from the largest liver leaves, the largest liver leaves are respectively placed in 10ml of centrifuge tubes containing 4% paraformaldehyde for fixation, and in order to ensure the tissue fixation effect, the centrifuge tubes are shaken every 10 minutes to prevent the tissue samples from sticking to the walls; and packaging the rest part with tinfoil paper, quickly freezing, storing at-80 ℃, and performing subsequent liver redox index determination.

Meanwhile, the stomach is found, along the intestinal tract structure: duodenum → jejunum (without chyme segment) → ileum (with partial chyme segment) → cecum (large part of the intestine section) → colon (with fecal-like particles segment), and find the cecum. Extruding cecal chyme in an aseptic operation, placing the chyme into a freezing storage tube, sticking the chyme with an adhesive tape, marking, and quickly throwing the chyme into a liquid nitrogen tank for subsequent determination of the flora of the cecal contents.

Accurately taking down abdominal fat of the mouse by using a scalpel (2 strips, weighing and recording, then taking a sample with the size of a small nail cover, putting the sample into a 10ml centrifugal tube containing fat fixing liquid, filling the fixing liquid by using a degreasing cotton plug, and preventing the fat sample from contacting air).

Observing the conditions of the spleen and the kidney of the mouse, weighing and recording one by one, carefully wrapping the mouse with tinfoil paper after weighing, marking the mouse, and storing the mouse in liquid nitrogen.

2 index determination

2.1 preparation of liver homogenate

Making a 10% homogenate: liver, making 10% liver homogenate with ice-bath normal saline at a ratio of 1:9 (mass to volume), centrifuging to obtain supernatant, and subpackaging at least 4 tubes with a volume of 300ul per tube, and storing at-80 deg.C for use. The protein concentration unit mgprot/ml is respectively used for measuring the total protein content (10 percent liver homogenate is diluted to 0.1 percent and then the total protein content of the liver is measured) and the anti-oxidation index.

2.2 weight Change, energy intake

Recording the feeding amount and the residual material amount of each mouse by taking repetition as a unit every day during the formal test period, calculating the average daily food consumption of each mouse in each group, and calculating the daily energy intake of each mouse by combining the composition of a daily ration formula; the mice were weighed every 3 days during the test period, and the average body weight of each mouse was plotted on the abscissa at 0 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks, and the growth curve of each mouse was plotted on the ordinate.

The change in body weight in mice at 12 weeks is shown in fig. 3, which shows that the body weight of mice was significantly increased in the high fat group compared to the low fat group; compared with a high-fat group, phloroglucinol has the advantages that the mouse weight increase is remarkably inhibited in a dosage mode, and the weight loss effect brought by the phloroglucinol with a higher dosage (0.1%) enables the mouse weight increase to approach a low-fat group.

Daily energy intake levels in 12 weeks of mice as shown in fig. 4, by comparing the energy intake of each group, it was found that only the low dose of phloroglucinol (0.025%) had a high energy intake in the group of mice, but even in the case of high energy intake, the low dose of phloroglucinol significantly reduced the body weight of the mice compared to the high fat group; compared with other groups, the other groups have no significant difference, and the influence caused by the feed intake (energy intake) is eliminated.

2.3 deposition of fat in abdomen and liver (abdominal fat weight, liver weight, abdominal fat rate, liver weight rate) and morphological observation of fat and liver tissue

During dissection, accurately weighing the weight of the abdominal fat lard and the surrounding fat, accurately recording the weight of the liver, dividing the weight of the abdominal fat lard and the surrounding fat by the weight of the fasting before slaughtering to obtain the corresponding abdominal fat rate and the liver weight rate, preparing a paraffin section and a frozen section of the liver tissue fixed by a fixing solution, respectively staining the paraffin section and the frozen section by hematoxylin-eosin (H & E) and staining the oil red, observing whether the liver tissue has large vesicular diffusion of fat cells, staining the abdominal fat paraffin section fixed by the fat fixing solution by H & E, and observing and counting the number of cells in a specific visual field of the size of the fat cells (counting method: counting up, counting left and right). The detailed steps of fixing, slicing and staining are as follows:

2.3.1 liver tissue, Abdominal fat sample fixation

Two parts of liver tissue with the size of the small nail cover and one part of abdominal adipose tissue with the size of the small nail cover are respectively put into a 10ml centrifugal tube containing a specific stationary liquid for fixing for more than 24 hours (during the period, the tissues are prevented from sticking to the wall, and the tissues are shaken according to the situation).

2.3.2 preparation of Paraffin section of liver tissue and Abdominal fat sample

(1) Material taking: taking out the tissue needing H & E from the fixing solution, flattening the tissue of a target part in a fume hood by using a scalpel, and placing the trimmed tissue and a corresponding label in a dehydration box; (2) dehydrating and wax dipping: and (5) putting the dehydration box into a hanging basket, and dehydrating by sequentially gradient alcohol in a dehydrating machine. 4h of 75% alcohol → 2h of 85% alcohol → 2h of 90% alcohol → 1h of 95% alcohol → 30min of absolute ethanol I → 30min of absolute ethanol II → 5-10 min of alcoholic benzene → 5-10 min of xylene I → 5-10 min of xylene II 5-10 min → 1h of 65 ℃ molten paraffin I1h → 1h of 65 ℃ molten paraffin II → 1h of 65 ℃ molten paraffin III; (3) embedding: embedding the wax-soaked tissue in an embedding machine. Firstly, molten wax is put into an embedding frame, tissues are taken out from a dehydration box and put into the embedding frame according to the requirements of an embedding surface before the wax is solidified, and corresponding labels are attached. Freezing at-20 deg.C, cooling, solidifying wax, taking out the wax block from the embedding frame, and trimming the wax block; (4) slicing: the trimmed wax block was sliced in a paraffin slicer to a thickness of 4 μm. The slices float on a spreading machine at 40 ℃ warm water to flatten the tissues, a glass slide picks up the tissues, and the slices are baked in a 60 ℃ oven. Baking with water, drying with wax, baking, and storing at room temperature.

2.3.3 liver tissue, Abdominal fat sample Paraffin section H & E staining

(1) Paraffin section dewaxing to water: sequentially placing the paraffin sections into dimethylbenzene I20 min → dimethylbenzene II 20min → absolute ethyl alcohol I5 min → absolute ethyl alcohol II 5min → 75% alcohol 5min, and washing with tap water; (2) hematoxylin staining: dyeing the slices in hematoxylin dyeing solution for 3-5 min, washing with tap water, differentiating the differentiation solution, washing with tap water, returning blue to the blue returning solution, and washing with running water; (3) eosin staining: the slices are dehydrated for 5min respectively by adding 85 percent and 95 percent gradient alcohol in sequence, and are dyed for 5min in eosin dye solution; (4) dewatering and sealing: placing the slices in anhydrous ethanol I5 min → anhydrous ethanol II 5min → anhydrous ethanol III 5min → xylene I5 min → xylene II 5min for transparency, and sealing with neutral gum; (5) microscopic examination and image acquisition and analysis are carried out to obtain an H & E image of the liver and an H & E image of abdominal fat.

Fig. 5 shows abdominal fat weight and abdominal fat rate of mice, and it can be seen that the high fat group significantly increased abdominal fat accumulation (abdominal fat weight) and significantly increased abdominal fat rate, while the addition of phloroglucinol was effective in reducing abdominal fat weight and abdominal fat rate. The abdominal fat H & E image is shown in fig. 6, and in different microscope views (left 100-fold lens view, right 300-fold lens view, scale 100 μm), the high fat group significantly increased the abdominal fat cell size compared to the low fat group, while phloroglucinol aldehyde inhibited the effect of high fat increasing the abdominal fat cell size. Further quantitative analysis is shown in fig. 7, which is a statistical analysis of the number of 400-fold under-the-lens abdominal adipocytes in fig. 7, compared to the low-fat group, the number of abdominal adipocytes in the high-fat group was significantly reduced, and the dose of phloroglucinol increased the number of abdominal adipocytes.

Fig. 8 shows liver weight and liver index of mice, high fat group significantly increased liver weight compared to low fat group, phloroglucinol significantly decreased liver weight compared to high fat group, and no significant difference in liver organ index among groups. The H & E and oil red staining patterns of the livers are shown in fig. 9, and compared with the low-fat group, the high-fat group had significant fat accumulation (white, 100 times of the shots in the left column), significant fat bullion accumulation (300 times of the shots in the middle column), and significant fat drop distribution (100 times of the shots in the right column), while phloroglucinol had the effect of significantly reversing the high-fat group.

2.3.4 preparation of frozen liver tissue sample sections

(1) Material taking: taking out the liver tissue needing to be made into oil red from the fixing solution, and flattening the tissue of a target part by using a scalpel; (2) and (3) dehydrating: placing the trimmed tissue in 15% sucrose solution, dehydrating and precipitating at 4 deg.C in a refrigerator, transferring into 30% sucrose solution, dehydrating and precipitating at 4 deg.C in a refrigerator; (3) OCT embedding: taking out the dehydrated tissue, slightly absorbing surface water with filter paper, placing the dehydrated tissue on an embedding platform with the section upward, dripping OCT embedding agent around the tissue, placing the embedding platform on a quick-freezing platform of a freezing microtome for quick-freezing embedding, and slicing after the OCT turns white and becomes hard; (4) slicing: fixing the embedding table on a slicing machine, roughly cutting to trim and level the tissue surface, then starting slicing, wherein the slicing thickness is 8-10 mu m, and flatly placing a clean glass slide on the cut tissue piece to stick the tissue on the glass slide. After the label is written on the slice, the slice is stored at the temperature of minus 20 ℃ for standby.

2.3.5 oil Red staining of frozen sections of liver tissue

(1) Freezing and fixing the section: rewarming and drying the frozen slices, fixing in a fixing solution for 15min, washing with tap water, and air drying; (2) oil red dyeing: putting the slices into oil red dye liquor for dip dyeing for 8-10 min (covering and keeping out of the sun); (3) background differentiation: taking out the slices, standing for 3s, sequentially immersing in 60% isopropanol in two cylinders for differentiation for 3s and 5s respectively. The slices are sequentially immersed in 2 cylinders of pure water for immersion cleaning for 10s each; (4) hematoxylin staining: taking out the slices, staying for 3s, immersing in hematoxylin for counterstaining for 3-5 min, and performing immersion washing in 3 cylinders for 5s, 10s and 30s respectively. Differentiating the slices with a differentiation solution (60% alcohol as a solvent) for 2-8 s, washing the slices with 2 cylinders of distilled water for 10s respectively, returning the blue liquid to blue for 1s, slightly immersing the slices in 2 cylinders of tap water for immersion washing for 5s and 10s respectively, and performing microscopic examination on the dyeing effect; (5) sealing: sealing with glycerol gelatin sealing agent; (6) microscopic examination and image acquisition and analysis are carried out to obtain a liver oil red image map (as shown in the right column of FIG. 9).

2.4 serum Biochemical indicators

Serum Total Cholesterol (TC), total Triglyceride (TG), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c), aspartate Aminotransferase (AST), and alanine Aminotransferase (ALT) were measured. The measuring instrument adopts a full-automatic biochemical analyzer BS-200 (Mirui, Shenzhen, China). All the sample measuring kits are purchased according to the related sample measuring kit appointed by the Mirey company, and the operation steps are completely carried out according to the instruction of the related sample measuring kit.

The results are shown in fig. 10 and fig. 11, fig. 10 is a histogram of serum transaminase content, in the case of liver damage, transaminase in mitochondria of liver cells is released, which results in elevation of serum transaminase, and the concentration of aspartate Aminotransferase (AST) and alanine Aminotransferase (ALT) in blood is compared with normal value in clinical liver function examination to reflect the liver damage. The graph shows that the high-fat group significantly increases serum transaminase (AST, ALT) concentration, and compared with the high-fat group, phloroglucinol aldehyde significantly reduces serum transaminase concentration in a dose-like manner.

FIG. 11 is a histogram of blood lipid levels, where the total triglyceride and total cholesterol levels in serum reflect the amount of lipid synthesis, LDL-cholesterol can transfer the lipids synthesized by the liver to the extrahepatic tissue, while HDL-cholesterol can transport the extrahepatic tissue lipids back to the liver for catabolism, so HDL-cholesterol has been recognized as "good cholesterol" or "lipid-clearing doffer". As can be seen, the high fat group significantly increased serum total triglycerides, total cholesterol levels, and significantly decreased the ratio of high density lipoprotein cholesterol to low density lipoprotein cholesterol compared to the low fat group, while phloroglucinol, especially at higher doses (0.1%), reversed this change in the high fat group.

2.5 determination of index of antioxidant ability of liver homogenate sample

The detection method and the steps of the oxidation resistance related indexes are detected according to the specification of a kit of Nanjing institute of bioengineering, and the detection indexes are superoxide dismutase (SOD) and Malondialdehyde (MDA).

The results are shown in fig. 12, and fig. 12 is a bar graph of the antioxidant index of liver tissue (taking 1% concentration of superoxide dismutase in liver homogenate and 10% concentration of malondialdehyde in liver homogenate as an example). Superoxide dismutase (SOD) in the liver can reflect the oxidation resistance of the liver, and malondialdehyde in the liver is an oxidative stress product, and the higher the concentration of the malondialdehyde in the liver, the more the oxidative stress is indicated to be serious. The graph shows that compared with the low-fat group, the high-fat group obviously reduces the concentration of superoxide dismutase in the liver and obviously improves the concentration of malondialdehyde in the liver, and compared with the high-fat group, the phloroglucinol aldehyde can obviously improve the concentration of superoxide dismutase in the liver and obviously reduce the concentration of malondialdehyde in the liver.

2.6 detection of the abundance of the bacterial flora in the cecal content

Approximately 0.5g of the cecal content from each mouse was sampled in the middle for subsequent analysis. The collection of the cecal contents is performed in a sterile manner. Cecal microbiota were identified by 16S RNA gene sequencing. The method mainly comprises the following steps:

2.6.1DNA extraction

After the cecal contents were thawed on ice, physiological saline was added, centrifuged and mixed thoroughly. The extraction method of DNA in the caecum content is carried out according to the instruction of a DNA extraction kit (Beijing Tiangen Biotechnology Co., Ltd., China), the detection and control of DNA quality are carried out by using a Nanodrop nucleic acid protein analyzer, and 30ng of DNA is taken for PCR amplification on the premise of qualified quality.

2.6.2PCR amplification

The V4 hypervariable region of the bacterial 16S rRNA gene was amplified by PCR with a forward primer sequence of 515a:5'-GTGCCAGCGCCGGTAA-3' and a reverse primer sequence of 806:5 '-GGACTACHVGGGTWTCTAAT-3'. For each cecal sample, a 10-digit barcode sequence was added to the 5' end of the forward and reverse primers (supplied by Allwegene, beijing, china), and each sample was tested in triplicate to reduce reaction level PCR bias. The PCR reaction was carried out in a total volume of 25. mu.L, containing 12.5. mu.L of 2xTaq PCR stock solution, 1. mu.L of the forward or 1. mu.L of the reverse primer (at a concentration of 5. mu.M, respectively), 3. mu.L of BSA (at a concentration of 2 ng/. mu.L), 3. mu.L of DNA sample (30ng), and 4.5. mu.L of double distilled water (ddH2O), respectively. The cycle parameters are: 95 ℃ for 5min, then 25 cycles at 95 ℃ for 45s, 50 ℃ for 50s, 72 ℃ for 45s, then extension at 72 ℃ for 10min, and finally 4 ℃ is completed. Running electrophoresis is needed after PCR amplification, the length and concentration of the generated amplified fragment are detected, if the length of the fragment is the length of the target fragment or the difference is not large, the amplification is successful, the detection parameter of agarose gel electrophoresis is 1% of gel concentration, the voltage is 170V, the electrophoresis time is 30min, three repeated PCR products of the same sample are mixed according to the equal density ratio, the three repeated PCR products are purified according to a GeneJET gel extraction kit (Schwerte Thermo Fisher scientific company, Germany), and the real-time PCR quantification is sequenced in the Allwegene company, Beijing. And (4) taking the sequencing result out of the machine and then carrying out analysis in the next step.

2.6.3 quality control and basic analysis of operational taxonomic units (otu)

The raw data sequenced by Miseq are first screened for chimeras with sequences shorter than 120bp, or with N sequences, or with fasta sequences in the uchime and denovo methods, from which they are deleted by the trimmatic (v0.36), pear (v0.9.6), flash (v1.20) and vsearch (v2.7.1) algorithms. After removing the barcode and primers, the raw data was obtained by splicing. The raw data yielded high quality sequences after further elimination of chimeras and short sequences. Sequence similarity of over 97% was clustered into operable taxa (otu) compared to the silva database.

2.6.4 taxonomic analysis

Otu representing < 0.005% of the population were removed and sorted by ribosomal database entry (rdp) sorter. Further analysis was performed at various levels of fungi (genus of genus Comamopsis, phylum), mainly phylum. The number of gates is expressed as mean ± standard deviation on the basis of relative abundance.

A histogram of significant changes in the bacterial population of the mouse is shown in FIG. 13 (class, order, family, and genus according to the bacterial classification scale p: phylum, c: order, g: genus). Metabolic syndrome patients (such as obese patients) are often accompanied by the change of the ratio of firmicutes to bacteroides in the intestinal flora, the ratio of the firmicutes to the bacteroides in the intestinal flora of the patients is often higher, and the verrucomicrobia (most of which are Ackermansia) is a beneficial bacterium and has an important role in relieving (improving) metabolic syndrome related diseases. As can be seen from the graph, the high-fat group significantly increased the ratio of firmicutes to bacteroides and decreased the relative content of beneficial bacteria (akkermansia) compared to the low-fat group, and phloroglucinol had a reversal effect compared to the high-fat group.

The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any changes or substitutions that can be easily conceived by those skilled in the art within the technical scope of the present invention are included in the scope of the present invention. Therefore, the protection scope of the present invention shall be subject to the protection scope of the appended claims.

Sequence listing

<110> Hunan agriculture university

Beijing Zhongnong Hongkong Biotechnology Co Ltd

Application of <120> phloroglucinol aldehyde and composition containing phloroglucinol aldehyde

<160>2

<170>SIPOSequenceListing 1.0

<210>1

<211>16

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>1

gtgccagcgc cggtaa 16

<210>2

<211>20

<212>DNA

<213> Artificial Sequence (Artificial Sequence)

<400>2

ggactachvg ggtwtctaat 20

Claims

1. Use of phloroglucinol in the manufacture of a product for preventing and/or ameliorating symptoms caused by high-energy dietary intake, wherein the phloroglucinol aldehyde is used as an active ingredient; the symptoms include obesity, metabolic diseases caused by excessive fat, liver function impairment, and intestinal flora disorder.

2. Use according to claim 1, wherein the high energy diet is a high fat diet.

3. Use according to claim 1, wherein the metabolic disease caused by excess fat comprises type II diabetes, metabolic syndrome, cardiovascular disease, chronic kidney disease, breast cancer, colorectal cancer.

4. The use of claim 1, wherein the impaired liver function comprises an increase in serum transaminase level, an increase in total liver cholesterol level, an increase in total liver triglyceride level, an increase in liver free radicals, a decrease in high density lipoprotein cholesterol level, a decrease in the ratio of high density lipoprotein cholesterol to low density lipoprotein cholesterol.

5. Use according to any one of claims 1 to 4, wherein the phloroglucinol is present in an amount of from 0.025 to 0.4% by weight, based on the total weight of the product.

6. A composition comprising (1) phloroglucinol, and (2) a pharmaceutically, food or feed acceptable excipient, wherein the phloroglucinol is present in the composition at a concentration that prevents and/or ameliorates symptoms caused by high-energy dietary intake; the symptoms comprise obesity, metabolic diseases caused by excessive fat, liver function impairment and intestinal flora disorder; the composition is a medicine, food or feed.

7. The composition of claim 6, wherein the phloroglucinol aldehyde comprises from 0.025 to 0.4 wt% based on the total weight of the composition.

8. The composition of claim 6, wherein the pharmaceutical, food or feed acceptable excipient is selected from the group consisting of: water soluble carrier or fat soluble carrier.

9. A high-fat diet comprising phloroglucinol as an active ingredient, for preventing and/or improving symptoms caused by intake of the high-fat diet, including obesity, metabolic diseases caused by excessive fat, impaired liver function, and intestinal flora disorder;

preferably, the phloroglucinol aldehyde accounts for 0.025-0.4 wt% of the total weight of the high-fat feed.

10. The method for preparing a high-fat diet as set forth in claim 9, comprising: crushing high-fat daily ration, and then uniformly mixing the crushed high-fat daily ration and phloroglucinol aldehyde in a step-by-step premixing mode;

preferably, the progressive premixing is at least three stages.

Preferably, after the high-fat ration and the phloroglucinol are uniformly mixed, the method further comprises the following steps: the resulting mixture was shaped.